Tenofovir disoproxil fumarate (TDF) is a potent and well tolerated drug, generally used in most of the scedule of antiretroviral treatment (ARV), however it is now known that its prolonged use can be associated with renal and bone toxicity. In several pivotal trials, tenofovir alafenamide (TAF), prodrug of TDF, showed lower toxicity while maintaining the same antiviral ability. Since October 2015 to Febraury 2017 in Italy was available compassionate use of once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F), and TAF 10 mg (E/C/F/TAF) for patients on ARV witha documented renal or bone impairment. The results of this real practice experience are here reported.
Compassionate use of tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: an Italian experience
NUNNARI, Giuseppe;
2017-01-01
Abstract
Tenofovir disoproxil fumarate (TDF) is a potent and well tolerated drug, generally used in most of the scedule of antiretroviral treatment (ARV), however it is now known that its prolonged use can be associated with renal and bone toxicity. In several pivotal trials, tenofovir alafenamide (TAF), prodrug of TDF, showed lower toxicity while maintaining the same antiviral ability. Since October 2015 to Febraury 2017 in Italy was available compassionate use of once-daily single tablet regimen of elvitegravir 150 mg (E), cobicistat 150 mg (C), emtricitabine 200 mg (F), and TAF 10 mg (E/C/F/TAF) for patients on ARV witha documented renal or bone impairment. The results of this real practice experience are here reported.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
